|
16 Dec 2019 |
Heat Biologics Announces First Patient Dosed in the First Phase 1 Trial of HS-130
|
|
15 Dec 2019 |
Gritstone Oncology Reports Promising Early Immunogenicity Activity and Safety Data from its Phase 1 Studies Evaluating its Neoantigen-based Immunotherapies, GRANITE and SLATE
|
|
13 Dec 2019 |
Soligenix Initiates Clinical Trial of its Heat Stable Ricin Toxin Vaccine
|
|
13 Dec 2019 |
Transgene Reports on the Combination Trial of TG4010, Chemotherapy and Nivolumab in Non-Small Cell Lung Cancer
|
|
11 Dec 2019 |
GemVax announced phase II results of GV1001 for Alzheimer's disease treatment at CTAD 2019
|
|
10 Dec 2019 |
Emergex Successfully Completes Preclinical Testing of its Lead ‘Set-Point’ Vaccine Candidate for Dengue Fever and Other Flaviviruses
|
|
09 Dec 2019 |
Nouscom - First Patient Dosed in a Phase 1 Trial With NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine, in MSI-High Solid Tumors
|
|
06 Dec 2019 |
Meissa Vaccines Receives FDA Clearance of IND Application for a Phase 1 Clinical Trial of MV-012-968 for Respiratory Syncytial Virus
|
|
05 Dec 2019 |
Osivax Enters Agreement with U.S. National Institutes of Health to Test Universal Flu Vaccine Candidate
|
|
04 Dec 2019 |
Advaxis Announces Submission of IND Application for ADXS-HOT Drug Candidate for Prostate Cancer
|
|
26 Nov 2019 |
Prokarium announces MHRA acceptance to run Phase I trial of lead vaccine against enteric fever
|
|
26 Nov 2019 |
Vaccitech Provides Update on Clinical Progress for its Two Phase 2 Universal Influenza Studies
|
|
24 Nov 2019 |
Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine Candidate at the American Society of Tropical Medicine and Hygiene (ASTMH) 68th Annual Meeting
|
|
23 Nov 2019 |
Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine Candidate
|
|
22 Nov 2019 |
Elios Therapeutics Presents Primary Analysis of Phase IIb Study Showing Personalized Cancer Vaccine Significantly Reduces Risk of Melanoma Recurrence in High-Risk Patients
|
|
22 Nov 2019 |
VBI Vaccines Presents Early GBM Tumor Response and Immunologic Data from Part B of Ongoing Phase 1/2a Study of VBI-1901 at the 2019 SNO Annual Meeting
|
|
19 Nov 2019 |
Enrollment and Randomization of 12,463 Participants Complete in BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trial
|
|
18 Nov 2019 |
Valneva Reports Excellent Final Phase 1 Results for its Chikungunya Vaccine Candidate, Confirms Plans
|
|
14 Nov 2019 |
VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection
|
|
12 Nov 2019 |
NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines
|
|
12 Nov 2019 |
Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union
|
|
11 Nov 2019 |
OSE Immunotherapeutics Presented Positive Correlation Between Neoepitope Response and Increased Survival for NSCLC Patients Treated with Tedopi®
|
|
09 Nov 2019 |
Neon Therapeutics Announces Updated Data Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
|
|
08 Nov 2019 |
Boston Biomedical, Inc. Highlights Phase 1 Data Evaluating Investigational WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S*) in Patients with Advanced Malignancies at SITC 2019
|
|
08 Nov 2019 |
Immutep presents positive interim data from phase II TACTI-002 trial at SITC
|
